Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Syntel target lowered to $23 at Needham — Business remains challenged but valuation could provide a floor for the stock (19.26)Needham lowers their SYNT tgt to $23 from $27. While SYNT's 4Q results were slightly ahead of expectations, mgmt introduced disappointing guidance for FY17, calling for a 2-7% decline in rev. Firm believes SYNT's higher exposure to the financial services and healthcare segments, where there is added uncertainty related to the regulatory envm't, combined with under-investment in emerging technologies, and increased competitive pressures is resulting in the recent under-performance compared to its peers. Firm reduces their ests in line with the guidance but maintaining BUY rating to reflect the historically low valuation level and potential for modest improvement over FY17 once client budgets are set and there is increased clarity on the regulatory climate in the financial services and healthcare segments; Buy.</td> </tr></table>"